Novo Nordisk to create the world's first all-diabetes professional cycling team

Novo NordiskNovo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.

Team Novo Nordisk will use life experiences and competitiveness to motivate people affected by diabetes. Throughout 2013, these athletes will compete in more than 500 sporting competitions around the world. The men's pro-cycling team will compete in races such as the USA Pro Cycling Challenge, the Tour of Britain and the Paris-Tours, with the ultimate goal of joining the Tour de France.

"As part of our long-standing Changing Diabetes® programme, this partnership provides a tremendous opportunity to raise awareness, and educate, empower and inspire people with diabetes," says Jakob Riis, senior vice president, Global Marketing and Global Medical Affairs, Novo Nordisk. "This is yet another way Novo Nordisk is striving to create more opportunities to live well with diabetes."

Phil Southerland founded what was known as 'Team Type 1' in 2005 and included riders and athletes with and without diabetes until this year. The new Team Novo Nordisk will only comprise of athletes who have diabetes and will continue to grow the team mission "to instil hope and inspiration for people around the world affected by diabetes."

"As Team Novo Nordisk we want to show the world what is possible with great diabetes control. Between us, Team Novo Nordisk has over 1,000 diagnosed years of diabetes with no complications and we stand for what life with diabetes can be like," Southerland says. "Exercise is that billion dollar drug that nobody ever gets prescribed, and in my experience is the best of them all. With appropriate diet, exercise, treatment and technology, anyone with diabetes can achieve their dreams."

About Diabetes
Today, 371 million people are living with diabetes.(1) Changing Diabetes® is Novo Nordisk's global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow. It is a global advocacy and partner platform which advocates for the prevention and early detection of diabetes, as well as improved treatment, care and health outcomes.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

1. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition, 2012 Update. Brussels, Belgium: International Diabetes Federation.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...